Ophthalmologic side effects during alpha-interferon therapy for viral hepatitis

Area of Science:

• Ophthalmology
• Hepatology
• Pharmacology

Background:

• Interferon therapy is associated with ophthalmologic side effects, including retinal lesions and neurovisual impairment.
• Viral hepatitis treatment often involves alpha-interferon, necessitating an understanding of its ocular risks.

Purpose of the Study:

• To prospectively assess the frequency and nature of ophthalmologic lesions during alpha-interferon treatment for viral hepatitis.
• To identify risk factors associated with retinopathy development during therapy.

Main Methods:

• A prospective study of 156 patients treated with alpha-interferon (standard or pegylated, with or without ribavirin) between 1995 and 2003.
• Regular ophthalmologic examinations were conducted before and during treatment.
• Statistical analysis identified risk factors for retinopathy.

Main Results:

• Retinopathy, including cotton-wool spots and retinal hemorrhages, occurred in 24% of patients and was asymptomatic.
• Neurovisual impairment affected 47% of patients during treatment, compared to 20% prior.
• Arterial hypertension, age over 45, and pegylated alpha-interferon use were significant risk factors for retinopathy.

Conclusions:

• Alpha-interferon therapy frequently causes retinopathy and neurovisual impairment, though typically asymptomatic.
• Continued alpha-interferon treatment may be feasible in asymptomatic patients with regular fundoscopic monitoring.
• Ophthalmologic surveillance is crucial for patients undergoing alpha-interferon therapy for viral hepatitis.